Overview

The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The main objective of study PLUS is to determine the potential benefits of individualized HCQ dosing schedules aimed at maintaining the whole-blood HCQ concentration above 1000 ng/ml
Phase:
Phase 4
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborator:
Sanofi-Synthelabo
Treatments:
Hydroxychloroquine